An in vitro method for predicting the efficacy of WBC separation using different starch preparations and anticoagulant ratios.
BACKGROUND
Separation of blood components depends on a number of factors, including the viscosity of the plasma and the number and size of the various cellular elements. To enhance granulocyte collection, it is common practice to alter the plasma environment by the addition of sedimenting agents such as hydroxyethyl starch. Recently, because of its prolonged persistence in the circulation, the higher-molecular-weight form of hydroxyethyl starch, Hespan (HP), has been replaced by the lower-molecular-weight form, pentastarch (PS). However, the yield appears to be lower. A rapid in vitro approach was used to permit comparison of the efficiency of separation of WBCs by the use of PS and HP and different ratios of anticoagulants that also alter the sedimenting characteristics of blood.


METHODS
Blood from individual persons was collected into sodium citrate at ratios of 1:8, 1:12, and 1:16. Samples were evaluated either before or after the addition of PS or HP and after centrifugation.


RESULTS
The addition of HP increased the sedimentation rate to at least four times that of plasma (10.9 vs. 47.9 mm); PS approximately doubled the rate. Viscosity was altered by the introduction of either starch. These changes (ranging from a rate of 4.2 in HP with a 1:16 anticoagulant to 3.6 in PS with a 1:8 ratio of anticoagulant) reflected the anticipated effects of anticoagulant dilution and carbohydrate addition. Granulocyte recovery was highest, with a 1:12 anticoagulant ratio in all tests with HP producing the greatest yield (HP, 101%; PS, 89%; control, 78%).


CONCLUSIONS
HP is far more effective than its lower-molecular-weight substitute PS in the generation of granulocytes in the buffy coat of whole blood. This method provides a simple, rapid, in vitro approach to evaluating the separating efficiency of solutions.
Rock
G
G
Division of Hematology and Transfusion Medicine, Ottawa Hospital, Civic Campus, Ottawa, Ontario, Canada. grock@ottawahospital.on.ca
Berger
R
R
Romans
R A
RA
Russell
N M
NM
Owens
W A
WA
D000925:Anticoagulants / Q000494:pharmacology*; D001799:Blood Sedimentation / Q000187:drug effects; D001809:Blood Viscosity / Q000187:drug effects; D002469:Cell Separation / Q000592:standards*; D005260:Female; D006801:Humans; D006895:Hydroxyethyl Starch Derivatives / Q000494:pharmacology*; D007962:Leukocytes / Q000166:cytology*; D008297:Male
D000925:Anticoagulants; D006895:Hydroxyethyl Starch Derivatives